

Analeptol 50 mg/ml + 50 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Authorised

- Diprophylline
- Heptaminol

Product identification

Medicine name:

Analeptol 50 mg/ml + 50 mg/ml solution for injection for cattle, horses, pigs, dogs and cats

Active substance:

Diprophylline
Heptaminol

Target species:

Cattle
Horse
Pig
Cattle (calf)
Horse (foal)
Pig (piglet)
Dog
Cat

Route of administration:

Intravenous use
Intraperitoneal use
Intramuscular use

Product details

Active substance and strength:

Diprophylline

50.00 milligram(s) / 1.00 millilitre(s)

Heptaminol

50.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intravenous use:

-

Cattle

- Meat and offal. 2 day
- Milk. 48 hour

-

Horse

- Meat and offal. 2 day
- Milk. 48 hour

-

Pig

- Meat and offal. 2 day

-

Cattle (calf)

- Meat and offal. 2 day

-

Horse (foal)

- Meat and offal. 2 day

•

Pig (piglet)

- Meat and offal. 2 day

Intraperitoneal use:

•

Cattle

- Meat and offal. 2 day

- Milk. 48 hour

•

Horse

- Meat and offal. 2 day

- Milk. 48 hour

•

Pig

- Meat and offal. 2 day

•

Cattle (calf)

- Meat and offal. 2 day

•

Horse (foal)

- Meat and offal. 2 day

•

Pig (piglet)

- Meat and offal. 2 day

Intramuscular use:

•

Cattle (calf)

- Meat and offal. 7 day

•

Horse (foal)

- Meat and offal. 7 day

•

Pig (piglet)

- Meat and offal. 7 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QR03DA51

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Carton box containing 1 clear type I glass vial containing 50 ml closed with a grey bromobutyl rubber stopper and aluminium cap.

Carton box containing 1 clear type I glass vial containing 20 ml closed with a grey bromobutyl rubber stopper and aluminium cap.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:

10/03/2023

Manufacturing sites for batch release:

CP-Pharma Handelsgesellschaft mbH

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 129522

Date of authorisation status change:

1/08/2023

Reference member state:

Netherlands

Procedure number:

NL/V/0379/001

Concerned member states:

Austria Belgium Estonia France Germany Hungary Ireland Italy Portugal
Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 28/07/2023

Download